Compile Data Set for Download or QSAR
Report error Found 229 Enz. Inhib. hit(s) with all data for entry = 3447
TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400703(US10000476, Compound I-62)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400699(US10000476, Compound I-64 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400698(US10000476, Compound I-57)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400699(US10000476, Compound I-64 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400700(US10000476, Compound I-59)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400231(US10000476, Compound I-1 | US10000476, Compound I-...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400697(US10000476, Compound I-56)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400690(US10000476, Compound I-49)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400691(US10000476, Compound I-50)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400692(US10000476, Compound I-51)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400693(US10000476, Compound I-52)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400718(US10000476, Compound I-77)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400719(US10000476, Compound I-78)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400720(US10000476, Compound I-79)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400721(US10000476, Compound I-80)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400714(US10000476, Compound I-73)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400715(US10000476, Compound I-74)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400716(US10000476, Compound I-75)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400710(US10000476, Compound I-69)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400712(US10000476, Compound I-71)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400713(US10000476, Compound I-72)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400706(US10000476, Compound I-65)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400707(US10000476, Compound I-66)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400708(US10000476, Compound I-67)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400734(US10000476, Compound I-93)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400735(US10000476, Compound I-94)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400736(US10000476, Compound I-96 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400736(US10000476, Compound I-96 | US10000476, Compound I...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400730(US10000476, Compound I-89)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400731(US10000476, Compound I-90)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400732(US10000476, Compound I-91)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400733(US10000476, Compound I-92)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400726(US10000476, Compound I-85)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400727(US10000476, Compound I-86)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400728(US10000476, Compound I-87)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400729(US10000476, Compound I-88)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400722(US10000476, Compound I-81)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400723(US10000476, Compound I-130 | US10000476, Compound ...)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400724(US10000476, Compound I-83)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400725(US10000476, Compound I-84)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400751(US10000476, Compound I-110)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400752(US10000476, Compound I-111)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400753(US10000476, Compound I-112)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400746(US10000476, Compound I-105)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400747(US10000476, Compound I-106)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400748(US10000476, Compound I-107)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400749(US10000476, Compound I-108)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400742(US10000476, Compound I-101)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400743(US10000476, Compound I-102)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetDisintegrin and metalloproteinase domain-containing protein 17(Human)
Kaken Pharmaceutical

US Patent
LigandPNGBDBM400744(US10000476, Compound I-103)
Affinity DataIC50: 100nMAssay Description:The TACE inhibition test was carried out by measuring TACE activity in the presence and the absence of the test substance using the thus-obtained TAC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

Displayed 1 to 50 (of 229 total ) | Next | Last >>
Jump to: